BPMC Blueprint Medicines
- 106.865
- +1.405+1.33%
Blueprint Medicines News
Blueprint Medicines Started at Buy by Stephens, Citing Ayvakit Franchise
Unveiling 18 Analyst Insights On Blueprint Medicines
Ratings for Blueprint Medicines (NASDAQ:BPMC) were provided by 18 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent
Blueprint Medicines Price Target Announced at $140.00/Share by Stephens & Co.
Blueprint Medicines Price Target Announced at $140.00/Share by Stephens & Co.
Blueprint Medicines Initiated at Overweight by Stephens & Co.
Blueprint Medicines Initiated at Overweight by Stephens & Co.
Stephens & Co. Initiates Coverage On Blueprint Medicines With Overweight Rating, Announces Price Target of $140
Stephens & Co. analyst Sudan Loganathan initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Overweight rating and announces Price Target of $140.
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
Blueprint Medicines(BPMC.US) Officer Sells US$1.05 Million in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Landsittel Michael sold 10,000 shares of common stock on May 2, 2024 at an average price of $105 for a total value of $1.05 million.Source: Announcement What is
Blueprint Medicines(BPMC.US) Officer Sells US$190.52K in Common Stock
$Blueprint Medicines(BPMC.US)$ Officer Hurley Ariel sold 1,834 shares of common stock on May 2, 2024 at an average price of $103.88 for a total value of $190.52K.Source: Announcement What is statement
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing
Michael Landsittel, CFO, on May 02, 2024, sold 10,000 shares in Blueprint Medicines (BPMC) for $1,050,000. Following the Form 4 filing with the SEC, Landsittel has control over a total of 47,286 share
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), today announced that, effective May 1, 2024, the Compensation Committee of Blueprint Medicines' Board of
Blueprint Medicines Price Target Raised to $97.00/Share From $50.00 by Leerink Partners
Blueprint Medicines Price Target Raised to $97.00/Share From $50.00 by Leerink Partners
Leerink Partners Upgrades Blueprint Medicines to Market Perform, Raises Price Target to $97
Leerink Partners analyst Andrew Berens upgrades Blueprint Medicines from Underperform to Market Perform and raises the price target from $50 to $97.
Blueprint Medicines Is Maintained at Buy by Goldman Sachs
Blueprint Medicines Is Maintained at Buy by Goldman Sachs
Goldman Sachs: Maintains Blueprint Medicines (BPMC.US) rating, adjusted from buy to buy rating, and adjusted target price from $121.00 to $168.00.
Goldman Sachs: Maintains Blueprint Medicines (BPMC.US) rating, adjusted from buy to buy rating, and adjusted target price from $121.00 to $168.00.
Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168
Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $121 to $168.
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97
Blueprint Medicines (BPMC) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $75 to $168.
Blueprint Medicines Is Maintained at Buy by HC Wainwright & Co.
Blueprint Medicines Is Maintained at Buy by HC Wainwright & Co.
Blueprint Medicines Price Target Raised to $135.00/Share From $125.00 by HC Wainwright & Co.
Blueprint Medicines Price Target Raised to $135.00/Share From $125.00 by HC Wainwright & Co.
HC Wainwright & Co. : The Blueprint Medicines (BPMC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $125.00 to $135.00.
HC Wainwright & Co. : The Blueprint Medicines (BPMC.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $125.00 to $135.00.
JMP Securities Maintains Market Outperform on Blueprint Medicines, Raises Price Target to $125
JMP Securities analyst Reni Benjamin maintains Blueprint Medicines (NASDAQ:BPMC) with a Market Outperform and raises the price target from $114 to $125.
Analysis
Price Target
No Data
